Canada Markets open in 5 hrs 4 mins

LexaGene Holdings Inc. (LXXGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1748-0.0008 (-0.43%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1756
Open0.1828
BidN/A x N/A
AskN/A x N/A
Day's Range0.1700 - 0.1828
52 Week Range0.0500 - 0.3860
Volume115,195
Avg. Volume180,248
Market Cap20.822M
Beta (5Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.0950
Earnings DateJun 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    LexaGene Successfully Completes Statement of Work for BioPharma Company

    BEVERLY, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce the completion of a validation study with a major biopharma company that recently purchased a MiQLab System for the possible use of the technology in its manufacturing processes. Dr. Jack Regan, LexaGene’s CEO and Founder co

  • GlobeNewswire

    LexaGene Closes Secured Convertible Note Transaction

    BEVERLY, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it has issued a 12% secured convertible note (the “Note”) to Meridian LGH Holdings 2, LLC, an affiliate of an insider of the Company, in the aggregate principal amount of up to USD$1,600,000. The Note matures on March 1, 2023. The Note is s

  • GlobeNewswire

    LexaGene Holdings Proposes to Amend Warrants Terms

    BEVERLY, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System for automated multiplex PCR testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on October 29, 2019. An aggregate of 12,769,626 Warrants were initially issued with an exercise price of CAD$0.75 per common